Survival in COPD patients treated with bronchoscopic lung volume reduction. (May 2022)

• Record Type: Journal Article
• Authors: Hartman, Jorine E.; Welling, Jorrit B.A.; Klooster, Karin; Carpaij, Orestes A.; Augustijn, Sonja W.S.; Slebos, Dirk-Jan
• Is Part Of: Respiratory medicine. Volume 196(2022)
• Publication Date: 2022-05
• Subjects: Bronchoscopy -- Chronic obstructive pulmonary disease (COPD) -- Survival; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2022.106825
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Background and objective: Severe COPD patients can significantly benefit from bronchoscopic lung volume reduction (BLVR) treatments with coils or endobronchial valves. However, the potential impact of BLVR on survival is less understood. Therefore, our aim was to investigate the survival rate in patients who are evaluated for BLVR treatment and whether there is a difference in survival rate between patients who undergo BLVR treatment and patients who do not. Methods: We included patients with COPD who visited our hospital for a consultation evaluating their eligibility for BLVR treatment and who performed pulmonary function tests during this visit. Furthermore, vital status was verified. Results: In total 1471 patients were included (63% female, mean age 61 years). A total of 531 patients (35%) died during follow-up and the median survival time of the total population was 2694 days (95% confidence interval(CI) 2462–2926) which is approximately 7.4 years. The median survival time of patients who were treated with BLVR was significantly longer compared to patients who were not treated with BLVR (3133 days versus 2503 days, p < 0.001), and BLVR was found to be an independent predictor of survival when adjusting for other survival-influencing factors such as age, gender or severity of disease. Conclusions: Our results suggest that bronchoscopically reducing lung volume in patients with severe hyperinflation may lead to a survival benefit for a population with a severely reduced life expectancy. Highlights: Median survival time after bronchoscopic lung volume reduction was 8.6 years. Survival time in treated patients was longer than in non-treated patients. Bronchoscopic lung volume reduction can lead to a survival benefit.